VivoSeq
Other

Systemic

5

Pipeline Programs↗

13

Active Trials↗

21

Companies Involved↗

Systemic is an early-stage landscape with 5 programs across 21 companies. The most active players are Novartis, AbbVie, Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

22/100

Mech. Concentration

33/100

Completion Rate

89/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 1AbbVie logo

AbbVie

1 program

PreclinicalJohnson & Johnson logo

Johnson & Johnson

1 program

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalA

Aerie Pharmaceuticals

0 programs

PreclinicalD

DUSA Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

61

clinical trials

Completed39 · 64%
Recruiting5 · 8%
Not yet recruiting4 · 7%
Terminated4 · 7%
Active, not recruiting4 · 7%
Unknown status3 · 5%
Other2 · 3%

Clinical Trials

Trial Activity

61 trials

Retinal Microvascularization in OCT-angiography and Systemic Diseases
Recruiting·—·N/A·NCT06613555·5,000 enrolled
TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts
Recruiting·HHuashan Hospital·Phase 3·NCT06022146·3,520 enrolled
Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact
Recruiting·MMedical University of Vienna·N/A·NCT05042830·30 enrolled
Hungarian National Systemic Amyloidosis Registry (AMYREG) - A Multi-Center, Longitudinal, Observational Survey of Patients With Systemic Amyloidosis
Recruiting·SSemmelweis University·N/A·NCT07689331·300 enrolled
Optimize First-line Treatment for Systemic Light Chain Amyloidosis With t (11; 14)
Recruiting·JJin Lu, MD·Preclinical·NCT06192979·41 enrolled
Safety, Tolerability, and Systemic Exposure of Apo-Si- K170A-C76 in Healthy Volunteers
Active, not recruiting·IInterna Therapeutics Ltd.·Phase 1·NCT07095049·56 enrolled
CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults
Active, not recruiting·UUniversity of Maryland, Baltimore·Phase 4·NCT03970304·87 enrolled
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
Active, not recruiting·AAllyx Therapeutics·Phase 1·NCT06632990·36 enrolled
A Phase Ib, Open-label, Ascending Dose Study With Step-up Doses to Assess Safety, Tolerability, and Pharmacokinetics of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
Active, not recruiting·Novartis logoNovartis·Phase 1·NCT06335979·54 enrolled
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Not yet recruiting·—·Phase 1·NCT07341867·90 enrolled
Effects of Mouthwashes on the Oral Microbiome and Systemic Health
Not yet recruiting·UUniversity of Plymouth·Phase 1·NCT07356271·200 enrolled
Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female Runners
Not yet recruiting·FFrench Cardiology Society·N/A·NCT07372859·120 enrolled
Effect of Systemic Retinoic Acid Use on Micro Ribonucleic Acid (mRNA) Expression
Not yet recruiting·MMedipol University·N/A·NCT07142070·25 enrolled
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
Completed·AbbVie logoAbbVie·Phase 1·NCT02420730·77 enrolled
Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations
Completed·BBausch & Lomb Incorporated·Phase 1·NCT03098953·15 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)